RFX1

Across TCGA pan-cancer cohorts, RFX1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RFX1 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RFX1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RFX1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where RFX1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	III,IV	0.788	0.970	.006	23	view →
CCRCC	DFS	Tertile	II,III,IV	0.817	1.000	.008	15	view →
LUAD	DFS	Median	II,III,IV	1.000	0.798	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RFX1–HNSC (OS)

Open the HNSC breakdown →